*Patient verbatim and profile comes from hypothetical patient for illustrative purpose only

**Pictures courtesy of Prof. Maurer, Prof. Magerl and their patients.

Data from ASTERIA II; two other phase III studies (ASTERIA I and GLACIAL) were also conducted to assess efficacy and safety of Xolair® in inadequately controlled CSU patients

Xolair® 300mg vs. baseline at 12 weeks; p<0.001 vs placebo.

References: 1. Zuberbier T et al. Allergy 2014;69(7):868–887. 2. NHS choices website. Angioedema - Symptoms. Available at: http://www.nhs.uk/Conditions/Angioedema/Pages/Symptoms.aspx. Accessed June 2016. 3. Maurer M, et al. N Engl J Med 2013;368:924-935. 4. Guidelines developed by European Academy of Allergy and Clinical Immunology, Global Allergy and Asthma European Network, European Dermatology Forum and the World Allergy Organization. 5. Zuberbier T et al. Allergy 2014; 69:868-887

NP4 code: GLDEIM/IGE025E/0181

Terms of use - Privacy policy - About cookies - Cookie Settings - This site is intended for a global audience.

© 2017 Novartis Pharma